Bo H. Chao

1.8k total citations · 1 hit paper
49 papers, 1.3k citations indexed

About

Bo H. Chao is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Bo H. Chao has authored 49 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 11 papers in Cancer Research. Recurrent topics in Bo H. Chao's work include Lung Cancer Treatments and Mutations (23 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Cancer Genomics and Diagnostics (10 papers). Bo H. Chao is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Cancer Genomics and Diagnostics (10 papers). Bo H. Chao collaborates with scholars based in United States, France and China. Bo H. Chao's co-authors include Leena Gandhi, Mark A. Socinski, Sai‐Hong Ignatius Ou, D. Ross Camidge, Hossein Borghaei, Shirish M. Gadgeel, Bogdana Balas, Alberto Chiappori, Tarek Mekhail and Gregory J. Riely and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Bo H. Chao

47 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

2015 462 citations Alice T. Shaw, Leena Gandhi et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Bo H. Chao

Since Specialization

Citations

This map shows the geographic impact of Bo H. Chao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo H. Chao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo H. Chao more than expected).

Fields of papers citing papers by Bo H. Chao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bo H. Chao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo H. Chao. The network helps show where Bo H. Chao may publish in the future.

Co-authorship network of co-authors of Bo H. Chao

This figure shows the co-authorship network connecting the top 25 collaborators of Bo H. Chao. A scholar is included among the top collaborators of Bo H. Chao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bo H. Chao. Bo H. Chao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Policy Evolution of China’s Critical Metals: An Integrated Analysis of Instruments and Networks 2025 ·Sustainability ·Zhen Wang, (unknown), Bo H. Chao, Yang Tai	0
2	Dual-functional improvement of vascularization and bone formation of complementary PRP-based gel scaffold 2025 ·Chemical Engineering Journal ·Han Zhang, Zhonghan Wang, Yang Wang, He Liu, Mufeng Li, Bo H. Chao, (unknown), (unknown), Minfei Wu	2
3	Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer 2023 ·Frontiers in Oncology ·Jonathan W. Goldman, Lynette M. Sholl, Sanja Đačić, Michael C. Fishbein, Yonina R. Murciano‐Goroff, Ravi Rajaram, (unknown), Anna M. Szpurka, Bo H. Chao, Alexander Drilon	3
4	Comprehensive evaluation and advanced modification of polymethylmethacrylate cement in bone tumor treatment 2023 ·Journal of Materials Chemistry B ·Bo H. Chao, Jianhang Jiao, Lili Yang, Yang Wang, Tong Yu, He Liu, Han Zhang, Mufeng Li, Wenjie Wang, (unknown), (unknown), Zhonghan Wang, (unknown)	3
5	TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data 2021 ·Blood ·Sarit Assouline, Amitkumar Mehta, Tycel Phillips, Lapo Alinari, Alexey V. Danilov, Stéphane Doucet, Steven I. Park, Deborah Berg, (unknown), (unknown), Bo H. Chao, Allison Berger, John F. Gibbs, Sharon Friedlander, Christine K. Ward, Igor Proscurshim, Brenda Cooper, Paolo F. Caimi	4
6	476 First-in-human phase 1/2 study of the first-in-class SUMO-activating enzyme inhibitor TAK-981 in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma: phase 1 results 2021 ·Regular and Young Investigator Award Abstracts ·Arkadiusz Z. Dudek, Dejan Juric, Afshin Dowlati, Ulka N. Vaishampayan, (unknown), Jordi Rodón, Bo H. Chao, Bingxia Wang, John F. Gibbs, Vaishali Shinde, Sharon Friedlander, Allison Berger, Christine K. Ward, (unknown), Robert Gharavi, (unknown), Igor Proscurshim, Anthony J. Olszanski	10
7	Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR -mutant Non–small Cell Lung Cancer 2020 ·Clinical Cancer Research ·Helena A. Yu, Luis Paz‐Ares, James Chih‐Hsin Yang, Ki Hyeong Lee, Pilar Garrido, Keunchil Park, Joo-Hang Kim, Dae Ho Lee, Huzhang Mao, Sameera R. Wijayawardana, Ling Gao, Rebecca R. Hozak, Bo H. Chao, David Planchard	31
8	Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2) 2020 ·Journal of Thoracic Oncology ·David R. Spigel, Robert M. Jotte, John Nemunaitis, (unknown), Jeffrey Schneider, Jerome H. Goldschmidt, (unknown), David Berz, Lasika Seneviratne, (unknown), (unknown), Kartik Konduri, Meng Xia, Hong Wang, Rebecca R. Hozak, Ivelina Gueorguieva, David Ferry, Leena Gandhi, Bo H. Chao, Igor I. Rybkin	36
9	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC 2020 ·Journal of Thoracic Oncology ·Roy S. Herbst, (unknown), Johanna C. Bendell, Edward Arrowsmith, Martin Wermke, (unknown), Nicolas Penel, Rafael Santana-Dávila, Helge Bischoff, Ian Chau, Gu Mi, (unknown), Erik Rasmussen, David Ferry, Bo H. Chao, Luis Paz‐Ares	44
10	Effects of Inulin Propionate Ester on Obesity-Related Metabolic Syndrome and Intestinal Microbial Homeostasis in Diet-Induced Obese Mice 2020 ·ACS Omega ·(unknown), (unknown), Xuelu Gao, (unknown), Yang Hou, (unknown), (unknown), Bo H. Chao, (unknown), Xinrui Li, Hanhan Zhang	19
11	FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC 2018 ·Journal of Thoracic Oncology ·David R. Spigel, Jamie E. Chaft, Scott Gettinger, Bo H. Chao, Luc Dirix, Peter Schmid, Laura Q.M. Chow, Rodney J. Hicks, Larry Leon, Jill Fredrickson, Marcin Kowanetz, Alan Sandler, Roel Funke, Naiyer A. Rizvi	114
12	MA26.10 CNS Activity of Ramucirumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant NSCLC 2018 ·Journal of Thoracic Oncology ·L. Paz-Ares, David Planchard, James Chih‐Hsin Yang, Kyoung Bun Lee, Pilar Garrido, K. Park, Jinna Kim, Daniel Lee, (unknown), Bo H. Chao, Helena A. Yu	2
13	MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer 2017 ·Journal of Thoracic Oncology ·D. Ross Camidge, Shirish M. Gadgeel, (unknown), Leena Gandhi, Gregory J. Riely, Jeremy Cetnar, Howard West, Mark A. Socinski, Alberto Chiappori, Tarek Mekhail, Bo H. Chao, Hossein Borghaei, Kathryn A. Gold, Walter Bordogna, Bogdana Balas, Johannes Noé, Sophie Golding, Ali Zeaiter, Alice T. Shaw	10
14	Epidermal growth factor receptor (EGFR) mutations in small cell lung cancers: Two cases and a review of the literature 2016 ·Lung Cancer ·Bradford Siegele, Konstantin Shilo, Bo H. Chao, David P. Carbone, Weiqiang Zhao, Olga B. Ioffe, Wilbur A. Franklin, Martin J. Edelman, Dara L. Aisner	14
15	Novel CHOP activator LGH00168 induces necroptosis in A549 human lung cancer cells via ROS-mediated ER stress and NF-κB inhibition 2016 ·Acta Pharmacologica Sinica ·Yiming Ma, Yanmin Peng, Qionghua Zhu, Anhui Gao, Bo H. Chao, Qiaojun He, Jia Li, Youhong Hu, Yubo Zhou	55
16	Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial breakdown → 2015 ·The Lancet Oncology ·Alice T. Shaw, Leena Gandhi, Shirish M. Gadgeel, Gregory J. Riely, Jeremy Cetnar, Howard West, D. Ross Camidge, Mark A. Socinski, Alberto Chiappori, Tarek Mekhail, Bo H. Chao, Hossein Borghaei, Kathryn A. Gold, Ali Zeaiter, Walter Bordogna, Bogdana Balas, Óscar Puig, Volkmar Henschel, Sai‐Hong Ignatius Ou	462
17	PGVL Hub: An Integrated Desktop Tool for Medicinal Chemists to Streamline Design and Synthesis of Chemical Libraries and Singleton Compounds 2010 ·Methods in molecular biology ·Zhengwei Peng, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Qiyue Hu, (unknown), Joe Z. Zhou, (unknown), Bo H. Chao, Shogo Ito, Jocalyn Clark, Nunzio Sciammetta, (unknown), Chris L. Waller, Atsuo Kuki	10
18	Methicillin‐resistant Staphylococcus aureus bacteremia due to prostatic abscess 2009 ·Journal of Hospital Medicine ·Bo H. Chao, Jason M. Kidd, Alan Dow	9
19	Fatal Loeffler's endocarditis due to hypereosinophilic syndrome 2007 ·American Journal of Hematology ·Bo H. Chao, (unknown), John D. Grizzard, Thomas J. Smith	12
20	Pre-treatment inflammation induced by TNF-α augments cryosurgical injury on human prostate cancer 2004 ·Cryobiology ·Bo H. Chao, Xiaoming He, John C. Bischof	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact